Immunotherapy and Immune Responses · Journal article

Peptide Self‐Assembly for Enhanced Cancer Therapy via Immunogenic Programmed Cell Death: Ferroptosis, Pyroptosis, Necroptosis, and Cuproptosis

Macromolecular Rapid Communications · August 8, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative review of peptide self-assembly as a technological platform to enhance immunogenic programmed cell death (ferroptosis, pyroptosis, necroptosis, cuproptosis) in cancer therapy. The source does not report empirical trial data, clinical outcomes, or comparative efficacy; it organizes design principles and preclinical evidence to propose a framework for future development and clinical translation.

What was studied

Journal article.

Key findings

Non-apoptotic programmed cell death pathways offer high immunogenicity and ability to bypass resistance mechanisms compared to traditional apoptosis-driven strategies Peptide self-assembly technology enables enzyme-responsive morphological transformation, multivalent target binding, subcellular localization, and artificial enzyme mimicry for precise programmed cell death induction Current clinical application of peptide-based programmed cell death induction is limited by poor tumor specificity, off-target toxicity, and delivery inefficiency

Safety

Current clinical application of peptide-based programmed cell death induction is limited by poor tumor specificity, off-target toxicity, and delivery inefficiency

Who this may help

This review does not provide sufficient empirical evidence or clinical trial data to guide immediate clinical practice. It outlines a conceptual framework for future therapeutic development and serves as a reference for researchers designing peptide-based cancer immunotherapies, pending clinical validation.

Plain-language summary

This is a narrative review synthesizing mechanistic and preclinical evidence on peptide self-assembly platforms for triggering immunogenic cell death pathways; it raises theoretical frameworks and design principles rather than reporting empirical clinical outcomes.

Clinical bottom line

Caveats

No primary efficacy data, clinical trial results, or outcome metrics reported
No quantitative synthesis of included studies or meta-analytic pooling
Explicitly states clinical application is currently limited and that clinical translation remains future work
No direct comparison of different peptide self-assembly approaches or programmed cell death pathways in the same patient population

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Review article; no primary empirical study design reported.

Directness

limited

Discusses mechanistic pathways and preclinical platforms; clinical application explicitly stated as limited.

Consistency

insufficient

No comparative analysis or synthesis of conflicting results reported in text.

Risk of bias

insufficient

Review methodology and bias assessment not described in source.

Sample adequacy

insufficient

No quantitative synthesis or sample sizes provided for included studies.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

While immunotherapy has revolutionized cancer treatment, its clinical efficacy is still constrained by tumor heterogeneity, acquired drug resistance, and the immunosuppressive tumor microenvironment. Traditional apoptosis-driven cancer therapeutic strategies are often inefficient and immunologically silent. In contrast, non-apoptotic programmed cell death (PCD) pathways (ferroptosis, pyroptosis, necroptosis, and cuproptosis) offer high immunogenicity and the ability to bypass resistance mechanisms, yet their clinical application is limited by poor tumor specificity, off-target toxicity, and delivery inefficiency. Peptide self‑assembly technology has emerged as a powerful platform to address these challenges, enabling enzyme‑responsive morphological transformation, multivalent target binding, subcellular localization, multifunctional co‑assembly, and artificial enzyme mimicry for precise PCD induction. Despite significant progress, a systematic classification of how peptide assemblies trigger distinct PCD pathways is still lacking. This review categorizes peptide self‑assembly‑induced tumor cell death into five major themes, including ferroptosis, pyroptosis, necroptosis, cuproptosis, and combined death. By summarizing the design principles, key evidence, and anti‑tumor outcomes, this review highlights the unique advantages of peptide self‑assembly. It provides a theoretical foundation for developing peptide‑based precision cancer therapies and aims to guide future research toward clinical translation and personalized treatment.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Gaolin LiangHai‐Dong XuImmunotherapy and Immune ResponsesMengmeng MaoXinruo XingShasha NingYun‐Kai Chang